As of June 22, 2025, Elixxer Ltd's estimated intrinsic value ranges from $0.17 to $0.43 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|---|---|
Discounted Cash Flow (10Y) | $0.43 | -62.9% |
Discounted Cash Flow (5Y) | $0.17 | -85.1% |
Is Elixxer Ltd (ELXR.V) undervalued or overvalued?
With the current market price at $1.15, the stock appears to be significantly overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Elixxer Ltd's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 5.1% | 6.1% |
Adjusted beta | 0.36 | 1.03 |
Cost of equity | 5.7% | 11.1% |
Cost of debt | 5.0% | 5.0% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 0.62 | 0.62 |
After-tax WACC | 4.9% | 8.3% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
---|---|---|---|
5-Year Growth | $0 | $11M | 86.6% |
10-Year Growth | $0 | $14M | 75.0% |
5-Year EBITDA | $(1,234) | $(13)M | 111.2% |
10-Year EBITDA | $(1,234) | $(12)M | 127.8% |
Metric | Value |
---|---|
Market Capitalization | $13M |
Enterprise Value | $22M |
Trailing P/E | 0.00 |
Forward P/E | 0.00 |
Trailing EV/EBITDA | 3.10 |
Current Dividend Yield | 0.00% |
Dividend Growth Rate (5Y) | 0.00% |
Debt-to-Equity Ratio | 0.62 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Discounted Cash Flow (10Y) | 55% | $0.13 |
Discounted Cash Flow (5Y) | 45% | $0.04 |
Weighted Average | 100% | $0.31 |
Based on our comprehensive valuation analysis, Elixxer Ltd's weighted average intrinsic value is $0.31, which is approximately 73.0% below the current market price of $1.15.
Key investment considerations:
Given these factors, we believe Elixxer Ltd is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.